AT/RTs (atypical teratoid/rhabdoid tumours) of the CNS (central nervous system) are childhood malignancies associated with poor survival rates due to resistance to conventional treatments such as chemotherapy. We characterized a panel of human AT/RT and MRT (malignant rhabdoid tumour) cell lines for expression of RTKs (receptor tyrosine kinases) and their involvement in tumour growth and survival. When compared with normal brain tissue, AT/RT cell lines overexpressed the IR (insulin receptor) and the IGFIR (insulin-like growth factor-I receptor). Moreover, insulin was secreted by AT/RT cells grown in serum-free medium. Insulin potently activated Akt (also called protein kinase B) in AT/RT cells, as compared with other growth factors, such as epidermal growth factor. Pharmacological inhibitors, neutralizing antibodies, or RNAi (RNA interference) targeting the IR impaired the growth of AT/RT cell lines and induced apoptosis. Inhibitors of the PI3K (phosphoinositide 3-kinase)/Akt pathway also impaired basal and insulin-stimulated AT/RT cell proliferation. Experiments using RNAi and isoform-specific pharmacological inhibitors established a key role for the class I A PI3K p110α isoform in AT/RT cell growth and insulin signalling. Taken together, our results reveal a novel role for autocrine signalling by insulin and the IR in growth and survival of malignant human CNS tumour cells via the PI3K/Akt pathway.
INTRODUCTION
The AT/RT (atypical teratoid/rhabdoid tumour) is a highly malignant paediatric tumour of the CNS (central nervous system), which is characterized by unique clinical, biological and histological features [1] [2] [3] [4] . Patients with CNS AT/RT respond very poorly to chemotherapy and radiotherapy and thus the prognosis for this particular malignancy is very poor [4] [5] [6] . AT/RT is related to other rhabdoid tumours of the kidney [MRT (malignant rhabdoid tumour)] and soft tissues. Most of the rhabdoid tumours harbour inactivating biallelic alterations in the hSNF5 (Human SNF5)/INI1 gene, a tumour suppressor gene on chromosome 22 [7] [8] [9] . hSNF5/INI1 is a component of the ATP-dependent chromatin remodelling SWI/SNF complex [10] . There are multiple sets of mammalian SWI/SNF complexes, with varying subunit compositions, which play important roles in transcriptional regulation, through both activation and repression of gene transcription [10] [11] [12] . Mice with a targeted disruption of the INI1 gene developed tumours at a high frequency and the resulting tumours displayed loss of expression of the hSNF5/INI1 protein [13, 14] . Deletion of hSNF5/INI1 was recently reported to cooperate with p53 loss in oncogenic transformation in murine models [15, 16] . One of the mechanisms by which hSNF5/INI1 exerts its tumour suppressor function was shown to involve repression of cyclin D1 gene expression [17] . Targeting cyclin D1 gene expression was thus suggested to represent a novel therapeutic strategy for AT/RT [17, 18] .
The insulin/IGF (insulin-like growth factor) family of growth factors are part of an evolutionarily conserved signalling system with a critical role in the growth and development of many tissues as well as the regulation of overall growth and metabolism. This signalling system is characterized by a high complexity and involves multiple proteins including three receptors [IR (insulin receptor), IGFIR (IGF-I receptor) and IGF-II/M-6-PR (mannose 6-phosphate receptor)], three ligands (insulin, IGF-I and IGF-II) and six known types of circulating binding proteins [IGFBP1 (IGF-binding protein 1)-IGFBP6] [19, 20] . Both IGF-I and IGF-II bind to the IGFIR, although IGF-I shows a higher affinity than IGF-II [20] . Insulin, the main ligand for the IR, has an IGFIRbinding affinity that is much lower than that of IGF-I [19, 20] . The specific receptor for IGF-II, the M-6-PR, differs significantly from the IGFIR, possesses no tyrosine kinase activity and was reported to target IGF-II for lysosomal degradation [21, 22] . Signalling by the IGFIR plays a fundamental role in cell growth and malignant transformation and is an important inhibitor of apoptosis [23, 24] . The IGFIR is overexpressed in a variety of human tumours including malignant brain tumours [25] . Decreased receptor expression or impaired function was reported to induce a reversal of the transformed phenotype, apoptosis and a decrease in cellular radioresistance and chemoresistance [26] . The IGFIR has thus Abbreviations used: AT/RT, atypical teratoid/rhabdoid tumour; CNS, central nervous system; Cy3, indocarbocyanine; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; EGF, epidermal growth factor; EGFR, EGF receptor; ERK1/2, extracellular-signal-regulated kinase 1/2; FCS, foetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA, haemagglutinin; hSNF5, human SNF5; IGF, insulin-like growth factor; IGFBP1, IGF-binding protein 1; IGFIR, IGF-I receptor; IR, insulin receptor; M-6-PR, mannose 6-phosphate receptor; MRT, malignant rhabdoid tumour; mTOR, mammalian target of rapamycin; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PDX-1, pancreatic duodenal homeobox-1; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PTEN, phosphatase and tensin homologue deleted on chromosome 10; RNAi, RNA interference; RTKs, receptor tyrosine kinases; RT, reverse transcriptase; SCF, stem cell factor; shRNA, small-hairpin RNA; siRNAs, small interfering RNAs; S6K, S6 kinase; Tos-Lys-CH 2 Cl, tosyl-lysylchloromethane. 1 To whom correspondence should be addressed (email Alexandre.Arcaro@kispi.unizh.ch).
been proposed to be a target for the development of novel anticancer therapies [26] [27] [28] [29] . In medulloblastoma, targeting of the IGFIR with the inhibitor NVP-AEW541 [30] was recently shown to impair cell growth and survival [31] . In AT/RT cells, a recent report has shown that the IGFIR is involved in anti-apoptotic signalling and contributes to chemoresistance [32] . Less is known about the potential involvement of the related IR in human cancer, although its role has been described in the pathogenesis of certain malignancies [33] . A critical intracellular signalling mediator of the IGFIR is the PI3K (phosphoinositide 3-kinase)/Akt [also called PKB (protein kinase B)] pathway [27, 34, 35] . Indeed, PI3K signalling is implicated in the control of cell proliferation, survival and motility/ metastasis downstream of many different growth factor receptors [35, 36] . The importance of PI3K signalling in human cancer is highlighted by the fact that mutations in the tumour suppressor gene PTEN (phosphatase and tensin homologue deleted on chromosome 10) occur frequently in human tumours [36, 37] . PTEN is a phosphatase that antagonizes the action of PI3K by dephosphorylating the D-3 position of polyphosphoinositides [38] . Moreover, previous reports have described activating mutations in the PIK3CA gene encoding the catalytic p110α isoform of class I A PI3K in a variety of human cancers, including, breast, colon and ovarian cancers, as well as medulloblastoma [39, 40] .
In the present study, we have investigated the expression pattern and biological functions of components of the IR and IGFIR signalling system in human AT/RT and MRT cell lines. Moreover, we have evaluated the potential of targeting the IR or the IGFIR using RNAi (RNA interference), neutralizing antibodies or the inhibitor NVP-AEW541 [30] as an antiproliferative approach in AT/RT cells. Finally, we have investigated whether targeting downstream signalling mediators of the IR could suppress growth and induce apoptosis in AT/RT cell lines. Our findings describe for the first time a role for autocrine signalling by insulin and the IR in growth and survival of AT/RT cells, which involves the PI3K/Akt pathway.
MATERIALS AND METHODS

Reagents and antibodies
Antibodies against Akt/PKB, caspase 3, HA (haemagglutinin) epitope tag, ERK1/2 (extracellular-signal-regulated kinase 1/2), IGFIRβ, INI1, IRβ, lamin B, p110β and p110δ were obtained from Santa Cruz Biotechnology. Antibodies against activated ERK1/2 (Thr 202 /Tyr 204 ), activated Akt (Ser 473 ), and Thr 389 -phosphorylated S6K (S6 kinase) were from Cell Signaling Technology. The Akt inhibitor [1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-Omethyl-3-O-octadecylcarbonate], IGF-I, the IGFIR neutralizing antibody (clone αIR3), LY294002, rapamycin and PD98059 were from Calbiochem. The anti-β-tubulin antibody and insulin were from Sigma-Aldrich. The IR neutralizing antibody (clone 47-9) was from Biosource. The anti-p85α antibody was from Upstate Biotechnology. The antibody against p110α (clone U3A) was a generous gift from Dr A. Klippel (atugen, Berlin, Germany). NVP-AEW541 (Novartis Pharma), YM024, TGX-221 and IC87114 (ICOS Corporation) were dissolved in DMSO at 10 mM and diluted into cell culture medium just prior to use.
Cell lines and cell culture
The human MRT cell lines AS, LP, MON and STM [9] have been described previously. The DAOY medulloblastoma cell line was purchased from the A.T.C.C. (Rockville, MD, U.S.A.). The BT-12 and BT-16 human CNS AT/RT cell lines [32, 41] were gifts from Dr Jaclyn Biegel (The Children's Hospital of Philadelphia, PA, U.S.A.). These cell lines have been established from two infants with CNS AT/RT (BT-12 from a 6-week-old female; BT-16 from a 2-year-old male). They have been analysed for INI1 mutations by Dr Jaclyn Biegel and both contain INI1 mutations. Human AT/RT cell lines were grown in DMEM (Dulbecco's modified Eagle's medium; Life Technologies/Invitrogen) with 10 % (v/v) FCS (foetal calf serum) and penicillin/streptomycin/L-glutamine, and passaged every 3-5 days by trypsinization. Human MRT cell lines were grown in RPMI 1640 (Life Technologies/Invitrogen) with 10 % FCS and penicillin/streptomycin/L-glutamine. For serumstarving, the cells were incubated for 16 h in DMEM containing 0.5 % FCS. All cell cultures were maintained at 37
• C in a humidified atmosphere with 5 % CO 2 . • C and analysed by SDS/PAGE and Western blot with anti-caspase 3 antibodies.
ELISAs
AT/RT cells were seeded at 5 × 10 4 cells/well in 6-well plates (35 mm). After 3 h, the cells were washed three times in serumfree medium and incubated in 2 ml of DMEM containing penicillin/streptomycin/L-glutamine. After 5 days, the supernatants were collected, centrifuged to remove cellular contaminants and human insulin was quantified by using the AIA-PACK IRI immunoenzymometric assay (Tosoh Corporation). The background signal caused by the cell culture medium in the absence of cells was subtracted from the measured values.
Immunofluorescence
AT/RT cells were grown on coverslips and serum-starved for 24 h. The cells were then fixed with 4 % (w/v) paraformaldehyde in 1× PBS and permeabilized with methanol for 10 min at − 20
• C. The coverslips were blocked with 0.5 % (w/v) non-fat dry milk in 1× PBS for 1 h and incubated with anti-insulin antibody (1:50; Dako) or anti-IRβ (1:100; Santa Cruz Biotechnology) for 1 h. The detection was performed using secondary anti-guinea-pig antibody coupled with FITC, or anti-rabbit antibody coupled with Cy3 (indocarbocyanine). Pictures were taken at × 100 magnification with a Zeiss Axioskop fluorescence microscope.
Immunoprecipitations
AT/RT cells grown to confluence on 10 cm dishes were serumstarved and stimulated with growth factors for 10 min at 37
• C. After washing with ice-cold 1× PBS, the cells were lysed for 20 min on ice in 1 ml of lysis buffer [20 mM Hepes/NaOH, pH 7.4, 150 mM NaCl, 1 % (w/v) Triton X-100, 2 mM EDTA, 10 mM sodium fluoride, 10 % (w/v) glycerol, 1 mM PMSF, 5 mM benzamidine, 1 mM Tos-Lys-CH 2 Cl (tosyl-lysylchloromethane), 10 µM leupeptin, 10 µM pepstatin A, 2 mM Na 3 VO 4 (sodium orthovanadate), 10 mM 2-glycerophosphate and 10 mM NaF]. Immunoprecipitation was performed for 2 h at 4
• C with primary antibodies (diluted according to the manufacturer's instructions). Protein G-Sepharose CL-4B (Amersham Biosciences) was then added, and the incubation was continued for 1 h at 4
• C. The immunoprecipitates were washed three times in lysis buffer and resuspended in 1× gel-loading buffer. The samples were denatured for 3 min at 100
• C and analysed by SDS/PAGE and Western blot.
MS analysis
Samples (10 µl) were desalted using Millipore C18 ZipTips. An aliqust of 0.5 µl was applied directly to a prespotted AnchorChip TM target. After 3 min of incubation, 7 µl of washing solution (0.1 % trifluoroacetic acid) was added on the analyte solution and the whole droplet was removed after a few seconds. MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) mass spectra were acquired in linear mode using a Bruker Daltonics Autoflex TM mass spectrometer.
RT (reverse transcriptase)-PCR
Total cellular RNA was extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. For each RT-PCR, 2 µg of total RNA was used with the Qiagen One-Step RT-PCR kit. The following primers were used: insulin primer, sense 5 -CGTTCCCCGCACACTAGGTT-3 and antisense 5 -GCAGCCTTTGTGAACCAACAC-3 ; IGF-I primer, sense 5 -GTGCTGCTTTTGTGATTTCTT-3 and antisense 5 -GTCTTGGGCATGTCGGTGTGG-3 ; IGF-II primer, sense 5 -ATGGGGAAGTCGATGCTGGTG-3 and antisense 5 -ACG-GGGTATCTGGGGAAGTTG-3 ; PDX-1 (pancreatic duodenal homeobox-1) primer, sense 5 -CTGCGGAGCCGGAGGAGA-AC-3 and antisense 5 -TCTAGAACTACACAGAGAGC-3 ; GAPDH (glyceraldehyde-3-phosphate dehydrogenase) primer, sense 5 -GAAGGTGAAGGTCGGAGTC-3 and antisense 5 -GAAGATGGTGATGGGATTTC-3 . The reaction conditions were as follows: reverse transcription at 50
• C for 30 min, initial PCR activation at 95
• C for 15 min followed by 40 cycles at 95
• C for 15 s, 55
• C for 20 s and 72
• C for 40 s. The PCR products were analysed in 3 % (w/v) agarose gel.
SDS/PAGE and Western-blot analysis
Cellular lysates were prepared with lysis buffer [50 mM Hepes/NaOH, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 % Triton X-100, 1 % (w/v) deoxycholic acid, 0.1 % SDS, 10 % glycerol, 10 µM leupeptin, 10 µM pepstatin A, 1 mM PMSF, 5 mM iodoacetamide, 5 mM benzamidine, 1 mM Tos-Lys-CH 2 Cl, 2 mM Na 3 VO 4 , 10 mM 2-glycerophosphate and 10 mM NaF]. The cells were lysed for 20 min on ice, scraped and lysates were centrifuged at 12 000 g for 20 min at 4
• C. The supernatants were collected and normalized for protein content by using the BCA (bicinchoninic acid) protein assay kit (Pierce). One volume of 2× gel-loading buffer [100 mM Tris/HCl, pH 6.8, 4 % SDS, 200 mM DTT, 0.2 % (w/v) Bromophenol Blue and 20 % (w/v) glycerol] was then added to the samples, followed by denaturation for 3 min at 100
• C and analysed by SDS/PAGE. The gels were transferred on to a hydrophobic PVDF membrane (Hybond- P; Amersham Biosciences) by electrophoresis. The membranes were then blocked in 1× PBS, 5 % (w/v) BSA (phospho-specific antibodies) or 1× PBS/3 % non-fat dry milk (all other antibodies) for 16 h at 4
• C. The membranes were incubated with primary antibodies (diluted according to the manufacturer's protocol) for 16 h at 4
• C. After washing in 1× PBS and 0.1 % (w/v) Tween 20, the immunoblots were incubated with donkey anti-rabbit IgG or sheep anti-mouse IgG secondary antibodies (1:10 000 dilution) coupled with horseradish peroxidase (Amersham Biosciences) for 1 h at room temperature. After washing of the immunoblots, chemiluminescence was used for detection, using the ECL ® (enhanced chemiluminescence) Western blotting detection reagents (Amersham Biosciences) according to the manufacturer's protocol.
Transient and stable transfections in AT/RT cells
Human AT/RT cells were transiently transfected with Akt/PKB constructs in pUSE (Upstate Biotechnology), or with PI3K shRNA (small-hairpin RNA) constructs in pRETRO-SUPER [42] by using Lipofectamine TM 2000 (Invitrogen). The transfections were performed in 96-well plates (MTS assays) or 6-well plates (Western-blot analysis), using the amounts of DNA and Lipofectamine TM 2000 recommended by the manufacturer's protocol. Opti-MEM I medium (Invitrogen) was used for the transfection and replaced by growth medium after 24 h.
The siRNAs (small interfering RNAs) targeting the IRβ and IGFIRβ and non-targeting control siRNA were purchased from Dharmacon. The siRNAs were transfected into BT-12 or BT-16 cells using Lipofectamine TM 2000 (Invitrogen). The transfections were performed in 96-well plates (MTS assays) or 6-well plates (Western-blot analysis), using the amounts of siRNA and Lipofectamine TM 2000 recommended by the manufacturer's protocol. Opti-MEM I medium (Invitrogen) was used for the transfection and replaced by growth medium after 24 h. Cell responses were assessed 72 h post-transfection.
For stable expression BT-16 cells (in 10 cm dishes) were transfected with an HA-tagged INI1 construct in pcDNA3 (Invitrogen) or with empty vector using Lipofectamine TM (Invitrogen). The amounts of DNA and Lipofectamine TM used were as recommended by the manufacturer's protocol. After 48 h, the cells were diluted 1:10 in growth medium containing G418 (1.0 mg/ml). A population of resistant cells was expanded and analysed after selection. Western-blot analysis was used to confirm expression of HA-tagged INI1.
RESULTS
Expression of components of the IR and IGFIR signalling pathways in AT/RT cells
We characterized a panel of established human AT/RT cell lines (BT-12 and BT-16) [32, 41] , MRT lines (AS, LP, MON and STM) [9] and medulloblastoma (DAOY) for expression of RTKs (receptor tyrosine kinases) to study further their involvement in tumour cell proliferation and survival. Lysates from normal adult brain, foetal brain and foetal cerebellum were analysed in parallel as controls. Western-blot analysis revealed that MRT and AT/RT cell lines overexpressed the IR and IGFIR, as compared with the normal brain samples ( Figure 1A) . Expression of the EGFR [EGF (epidermal growth factor) receptor], ErbB2 and c-Kit were also detected in the panel of cell lines ( Figure 1A and results not shown). In contrast, the PDGFR (platelet-derived growth factor receptor) was not detected in the cell lines under study (results not shown). The expression of components of the PI3K/Akt signalling pathway in the panel of MRT and AT/RT cell lines was then investigated. All cell lines expressed the PI3K regulatory subunit p85α and the p110α and p110β catalytic subunits ( Figure 1A ). In addition, both AT/RT cell lines overexpressed the p110δ isoform ( Figure 1A ). MRT and AT/RT cell lines displayed comparable levels of IRS-1 (IR substrate-1), mTOR (mammalian target of rapamycin) and ERK1/2 ( Figure 1A and results not shown). The AT/RT and MRT cell lines did not express INI1, in contrast with DAOY medulloblastoma cells, as expected ( Figure 1B) . Indeed, AT/RT and MRT cell lines and tumours harbour inactivating biallelic alterations in the hSNF5/INI1 gene, leading to loss of expression of the INI1 protein [1, 9] . In contrast, these mutations are not found in medulloblastoma [43] .
Human AT/RT secrete insulin in an autocrine manner
We next investigated whether AT/RT cells produced growth factors in an autocrine fashion. An ELISA revealed that both BT-12 and BT-16 cell lines secreted insulin into the growth medium, when cultivated under serum-free conditions (Figure 2A) . The BT-16 cell line appeared to produce higher amounts of insulin than BT-12 (2628 pmol/l versus 867 pmol/l). IGF-I or IGF-II secretion could not be detected in either BT-12 or BT-16 cells grown in serum-free medium (results not shown). However, an RT-PCR analysis revealed that IGF-I mRNA was expressed in BT-16 cells, while IGF-II expression was detectable in BT-12 cells (see Supplementary Figure 1 at http://www.BiochemJ.org/bj/406/ bj4060057add.htm). To confirm that the growth factor secreted by BT-16 cells corresponded to human insulin, supernatants of BT-16 cells were analysed by MS. MS analysis revealed the presence of a protein of 5807 Da, corresponding to human insulin in serum-free supernatants obtained from BT-16 cells ( Figure 2B ). Immunofluorescence analysis revealed that individual BT-16 cells co-expressed insulin and the IR, indicating the presence of an autocrine signalling loop in these cells ( Figure 2C ). We next performed RT-PCR analysis to investigate the expression of the transcription factor PDX-1 in the panel of cell lines. PDX-1 is a master regulator of pancreas development and β-cell function, which participates in the transcription of several genes, including insulin [44] . This analysis revealed strong expression of PDX-1 mRNA in the BT-12, BT-16 and MRT cell lines, confirming their insulin-producing phenotype ( Figure 2D ). We next investigated whether other human cancer cell lines also secrete insulin under similar culture conditions. However, an analysis of a panel of human medulloblastoma and neuroblastoma cell lines failed to document insulin secretion under serum-free culture conditions (results not shown), indicating that the response is selective for CNS AT/RT cells.
Inhibition of AT/RT cell proliferation by targeting the IR
The specific IGFIR/IR kinase inhibitor NVP-AEW541 [30] inhibited proliferation of BT-12 and BT-16 cell lines (Figure 3A) , in a dose-dependent manner with IC 50 values of 2 µM in BT-12 and 5 µM in BT-16 cells ( Figure 3A) . In BT-12 cells, NVP-AEW541 was effective at slightly lower concentrations, when cells were incubated in medium containing low serum, as compared with high serum ( Figure 3A) . In contrast, no differences in sensitivities were observed in the BT-16 cell line ( Figure 3A) . To confirm these observations, cell proliferation of BT-12 or BT-16 cells was assessed in the presence of neutralizing antibodies specific either for the IGFIR or for the IR. Proliferation of BT-16 cells in serum-free medium was significantly inhibited by the anti-IR neutralizing antibody ( Figure 3B ). A similar effect was observed with the anti-IGFIR neutralizing antibody ( Figure 3B ). The anti-IR neutralizing antibody also significantly inhibited proliferation of BT-12 and BT-16 cells in serum-containing medium (results not shown). Increasing concentrations of insulin stimulated proliferation of BT-16 cells in serum-free medium ( Figure 3C ) and the response was completely inhibited by a pharmacological PI3K inhibitor (LY294002), indicating that PI3K is essential for insulin-stimulated cellular responses in AT/RT cells. The maximal increase in cell proliferation was observed at an insulin concentration of 50 ng/ml (8.6 nM) and concentrations up to 1000 ng/ml had no significantly higher effect ( Figure 3C ). Inhibiting IGFIR/IR function with NVP-AEW541 also induced apoptosis in AT/RT cells, as assessed by caspase 3 activation ( Figure 3D ), indicating that the autocrine signalling loop involving the IR contributes to cell survival.
An RNAi approach was used to confirm the critical role of the IR and IGFIR in supporting AT/RT cell growth and survival. Transfection of BT-12 and BT-16 cells with siRNA targeting either the IRβ or the IGFIRβ resulted in a significant decrease in cell viability ( Figures 4A and 4B and results not shown) . To verify the specificity of the effect of the siRNA targeting the IRβ, protein down-regulation was assessed by Western-blot analysis in BT-12 and BT-16 cells ( Figure 4C and results not shown).
Activation of the PI3K/Akt signalling pathway by insulin in AT/RT cells
The ability of polypeptide growth factors to activate PI3K/Akt, ERK1/2 and ribosomal protein S6K was then investigated in BT-12 and BT-16 cells. Insulin most potently activated Akt, as compared with EGF and SCF (stem cell factor), whereas activation of ERK1/2 was comparable between all growth factors (Figure 5A) . The IGFIR/IR kinase inhibitor NVP-AEW541 (2.5 µM) completely inhibited IGF-I-and insulin-activated responses ( Figure 5B) . Autophosphorylation of the IR was also detected in insulin-stimulated AT/RT cells, confirming the specificity of the responses observed ( Figure 5C ).
Our data so far had revealed activation of the PI3K/Akt, S6K and ERK1/2 pathways in AT/RT cells stimulated by polypeptide growth factors. Therefore we next investigated the contributions of these pathways to proliferation in BT-12 and BT-16 cells. Cell proliferation was assessed in the presence of the PI3K inhibitor LY294002, rapamycin, the MEK [MAPK (mitogenactivated protein kinase)/ERK kinase] inhibitor PD98059, or a pharmacological Akt/PKB inhibitor. AT/RT cell proliferation was significantly impaired by LY294002 or rapamycin, in both BT-12 and BT-16 cells grown in low (1 %) or high (10%) serum ( Figure 5D ). The Akt inhibitor completely inhibited proliferation of the BT-12 cell line in low, but not high serum, while having a lesser effect in the BT-16 cell line ( Figure 5D ). To confirm the involvement of PI3K/Akt signalling in AT/RT cell proliferation, a dominant-negative catalytically inactive Akt (AktDN) construct was transiently transfected into BT-12 and BT-16 cells. Westernblot analysis confirmed expression of the construct in AT/RT cells (results not shown). The AktDN construct significantly inhibited proliferation in both cell lines ( Figure 5E ). In contrast, transfection of an activated Akt mutant (myrAktCA) had no significant effect on AT/RT cell proliferation.
The class I A PI3K isoform p110α controls AT/RT cell proliferation and insulin-stimulated Akt activation
To confirm the involvement of PI3K signalling in AT/RT cell responses to insulin, a panel of isoform-specific class I A PI3K inhibitors was tested in AT/RT cells. The pharmacological p110α inhibitor YM024 [45] inhibited proliferation of AT/RT cells in a dose-dependent manner with an IC 50 of 1.5 µM (Figure 6A ). In contrast, the p110β inhibitor TGX-221 [46] and the p110δ inhibitor IC87114 [47] had a less pronounced effect on AT/RT cell proliferation ( Figure 6A ). The pharmacological p110α inhibitor YM024 also inhibited insulin-stimulated Akt activation, whereas TGX-221 and IC87114 did not impair the response (Figure 6B and results not shown). shRNA constructs targeting the catalytic subunits of class I A PI3Ks were then transiently transfected into BT-16 cells to investigate their impact on cell proliferation. Western-blot analysis confirmed down-regulation of the expression of the target genes by the relevant shRNA construct ( Figure 6D ). The shRNA constructs targeting PIK3CA (encoding p110α) strongly (> 80 %) inhibited BT-16 cell proliferation ( Figure 6C ). In contrast, RNAi targeting of PIK3CB resulted in no significant effect on AT/RT cell proliferation ( Figure 6C ). Moreover, insulin-stimulated Akt activation was abrogated by transfection of BT-16 cells with the shRNA construct targeting PIK3CA (results not shown). Thus the p110α isoform appears to play a crucial role in controlling AT/RT cell proliferation and insulin-stimulated Akt activation. Figure 7C) . Moreover, the expression levels of the IR and IGFIR were not affected, as assessed by Western-blot analysis ( Figure 7D ). These results indicate that the establishment of the autocrine loop involving insulin and its receptor is independent of INI1 loss in AT/RT cells.
DISCUSSION
Molecular abnormalities linked with human AT/RT include germline and somatic mutations in the INI1 gene that encodes a chromatin remodelling factor and has been suggested to function as a tumour suppressor [7] [8] [9] . A recent report has also documented epigenetic repression of the RASSF1 (Ras association domain family 1) gene in AT/RT cell lines and primary tumours [41] . RTK signalling has not yet been studied in detail in AT/RT cells. Expression of the IGFIR and IGF-II was reported in a limited number of cases of AT/RT tumours [25, 48] . Targeting the IGFIR with antisense oligonucleotides resulted in increased apoptosis and sensitivity to the chemotherapeutic agents cisplatin and doxorubicin in AT/RT cells [32] . In the case of the MRTs, the EGFR inhibitor gefitinib was reported to have anti-tumour effects in vitro and in vivo [49] . Moreover, the PI3K/Akt pathway was reported to be involved in the resistance of MRT cells to chemotherapy and radiotherapy [50] .
We have characterized a panel of human MRT and AT/RT cell lines for expression of RTKs and their downstream signalling mediators, in order to study the potential of targeting these molecules to inhibit cell proliferation and survival. The IR and IGFIR were found overexpressed in both AT/RT and MRT cell lines, as compared with normal brain tissue. Moreover and surprisingly, AT/RT cell lines secreted insulin when grown under serum-free conditions, indicating autocrine signalling events. To our knowledge these AT/RT cell lines are the first example of human CNS tumour cell lines secreting insulin. Moreover, the only other examples of insulin secretion by cells other than pancreatic β-cells are sperm cells [51] . The concentration of insulin measured in supernatants from BT-16 cells was 2.5 nM, which is in the biological range. Maximal biological responsiveness to insulin tends to occur at concentrations in the range 10-20 nM [52] [53] [54] and insulin had maximal effects on BT-16 cell proliferation at a concentration of 8.6 nM. It is conceivable that AT/RT cells also produce other growth factors in an autocrine fashion. Indeed, IGF-I and IGF-II were detected at the mRNA level in BT-16 and BT-12 cells respectively, as recently reported [32] . We were unable to detect free IGF-I and IGF-II in supernatants from AT/RT cells by ELISA, but this could be due to the fact that IGFs were bound to IGF-binding proteins. Autocrine signalling by IGF-I via the IGFIR in BT-16 cells would explain the inhibitory effects of IGFIR-neutralizing antibodies or siRNA on the proliferation of these cells.
Insulin activated PI3K/Akt, S6K and ERK signalling, whereas other growth factors such as EGF or SCF selectively activated some, but not all of the pathways. Targeting the IGFIR kinase activity with NVP-AEW541 resulted in inhibition of AT/RT proliferation, although at higher IC 50 values than reported in other tumour cells [30] . These increased IC 50 values possibly reflect co-expression of the IR and IGFIR in AT/RT cell lines, since the IC 50 of NVP-AEW541 for the IR was reported to be 2.3 µM in cells [30, 55] . This model was supported by the observations that neutralizing antibodies or siRNA targeting the IRβ inhibited the proliferation of AT/RT cells. Consequently, our results demonstrate that insulin secreted by AT/RT cells in an autocrine fashion activates the IR and thus contributes to AT/RT cell proliferation and survival. This mechanism of IR activation appears to be different from the previously reported activation loop involving IGF-II and the IR isoform A in human cancer cells [56] [57] [58] . The molecular mechanisms underlying the establishment of the autocrine insulin signalling loop in AT/RT cells are currently unclear. Loss of hSNF5/INI1 did not appear to be a major cause of the expression of insulin and the IR by AT/RT cells, since transfection of INI1 did not substantially alter the expression of these molecules. Intriguingly, the pancreatic transcription factor PDX-1 was detected in AT/RT and MRT cells, indicating that aberrant expression of transcription factors may drive these cancer cells towards an insulin-producing phenotype. A recent survey of mutations in human tumour genomes has revealed frequent mutations in transcription factors, emphasizing the contribution of abnormalities in transcription to the development of human cancer [59] .
To investigate whether targeting downstream signalling mediators of the IR could provide a means of inhibiting proliferation of AT/RT cells, we used a combination of pharmacological and RNAi approaches. This revealed that the PI3K/Akt/mTOR pathway was crucial in the control of AT/RT cell proliferation. Moreover, a selective role for the PI3K isoform p110α in transducing signals from the IR was uncovered in AT/RT cells, in good agreement with recent reports documenting the crucial role of p110α in insulin signalling [60, 61] . Thus pharmacological inhibitors targeting the PI3K p110α isoform may have antiproliferative potential in human cancer cells where this isoform is activated by the IR.
Insulin has various biological effects in a broad range of tissues, and its functions in the brain include neuronal survival and regulation of energy homoeostasis [62] . Although a large body of evidence exists implicating IGF-I and IGF-II as autocrine growth factors in a broad range of human malignancies [24, 27] , such a function has not yet been described for insulin in CNS tumours. In the light of the novel function for insulin as an autocrine growth factor for CNS AT/RT cells, further studies are warranted to uncover its potential role in other human cancers.
